[ad_1]
Integrating Electroporation Know-how & DNA Vaccine Platforms
HONG KONG SAR – Media OutReach – 20 September 2022 – Immuno Remedy BioTech, a medical stage biotechnology group primarily based within the Hong Kong Science Park specialising in DNA vaccines and immunotherapies, introduced at this time the acquisition of 92.6% of Shanghai Teresa Healthcare, the pioneer of electroporation know-how and machine in China. The transaction will likely be settled in money and shares. Teresa’s shareholders will swap for about 1.5% fairness in Immuno Remedy whereas the inventor of Teresa’s EP know-how, Professor XU Yuhong (徐宇虹), maintains her 7.4% direct fairness in Teresa.
Teresa EP machine delivers transient electrical pulses to advertise environment friendly penetration of DNA vaccine by cell membrane for the enhancement of gene expression and supreme immune responses. It’s the solely such machine permitted by Nationwide Medical Merchandise Administration for the administration of DNA vaccine in China. Such EP know-how has been an integral a part of Immuno Remedy’s DNA vaccine supply technique from analysis to medical stage.
Based in 2004, Shanghai Teresa is an revolutionary medical machine group focusing in electro immunotherapies and rehabilitation therapies. In 2005, Teresa’s electroporation know-how was developed to reinforce the supply of DNA drugs, primarily based on the mental property generated by Shanghai Jiao Tong College beneath the Nationwide 863 Challenge. Such EP know-how has been confirmed protected and efficacious after deployment of over 10,000 occasions in collaboration with greater than thirty hospitals for the administration of DNA drugs in quite a few human trial topics.
Immuno Remedy has two PD-1-Enhanced DNA vaccines at the moment in section 1 medical trial for prevention of COVID-19 and therapeutic treatment of HIV/AIDS.
Dr JIN Xia, CEO of Immuno Remedy mentioned, “Immuno Remedy has partnered with Teresa over time in creating customised EP supply technique for our PD-1-Enhanced DNA vaccines, which has led to encouraging ends in medical setting lately. I’m happy with this convergence with Teresa, which can little question deliver our groups even nearer collectively. Teresa will proceed to function independently whereas leveraging on Immuno Remedy’s R&D platform for the event of their subsequent era non-invasive EP know-how for intradermal supply technique. Immuno Remedy is dedicated to assist the continuous progress and success of Teresa.”
Ms. CHEN Liye, CEO of Teresa mentioned, “Based on our long run collaboration, Teresa is worked up to turn into a member of Immuno Remedy Group. This transfer won’t solely present us with a a lot nearer R&D relationship, which is crucial for our know-how development but additionally provide us the monetary functionality to satisfy future wants. Teresa treasures our collaborations with different gamers within the area and stay up for persevering with our collaborations with new and sustainable EP know-how.”
Professor CHEN Zhiwei, Director of AIDS Institute on the College of Hong Kong and the Principal Scientific Advisor of Immuno Remedy mentioned, “Our analysis and growth work on the AIDS Institute and Immuno Remedy has benefitted from Teresa’s EP know-how and their diligent collaborative effort over the previous 12 years. I’m happy to see their relationship creating into a fair nearer tie. Look ahead to the event of the subsequent era of EP know-how for additional optimisation of supply technique and affected person expertise.”
Dr Percy CHENG, Chairman of Immuno Remedy concludes, “This transaction affords Immuno Remedy the chance to safe Teresa’s EP know-how for assist of not solely R&D but additionally the medical administration of our PD-1-Enhanced DNA vaccines. We’re happy with Professor XU’s choice to stay as our co-investor in Teresa and are optimistic in the way forward for EP know-how in our DNA vaccine growth.”Hashtag: #ImmunoCureBiotech
The issuer is solely liable for the content material of this announcement.
Immuno Remedy BioTech
Immuno Remedy BioTech is a medical stage biotechnology group primarily based within the Hong Kong Science Park, specializing in analysis and growth of vaccines and immunotherapies for cancers, inflammatory and infectious ailments primarily based on its patented PD-1-Enhanced DNA vaccine and Anti-Δ42PD1 Blocking Antibody know-how platforms.
To be taught extra about Immuno Remedy BioTech, please go to 
www.immunocure.hk
Shanghai Teresa Healthcare
Based in 2004, Shanghai Teresa is an revolutionary medical machine group primarily based in Shanghai Zhangjiang Hello-Tech Park, focusing in electro immunotherapies and rehabilitation therapies.
To be taught extra about Shanghai Teresa Healthcare, please go to http://www.e-teresa.com http://www.teresabio.com
[ad_2]
Source link
